Related references
Note: Only part of the references are listed.Allosteric modulation of NMDA receptors alters neurotransmission in the striatum of a mouse model of Parkinson's disease
Ze-Jun Feng et al.
EXPERIMENTAL NEUROLOGY (2014)
GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease
Xiaoqun Zhang et al.
JOURNAL OF NEUROCHEMISTRY (2014)
Potentiation of GluN2C/D NMDA Receptor Subtypes in the Amygdala Facilitates the Retention of Fear and Extinction Learning in Mice
Kevin K. Ogden et al.
NEUROPSYCHOPHARMACOLOGY (2014)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: LIGAND-GATED ION CHANNELS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: G PROTEIN-COUPLED RECEPTORS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
Lorraine V. Kalia et al.
MOVEMENT DISORDERS (2013)
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Pierre Paoletti et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Plasticity of NMDA receptor-mediated excitatory postsynaptic currents at perforant path inputs to dendrite-targeting interneurons
Sarah C. Harney et al.
JOURNAL OF PHYSIOLOGY-LONDON (2012)
Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors
Hui Zhang et al.
BASAL GANGLIA (2012)
The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D2/A2A Receptor Interaction in the Striatum: Implications for Parkinson's Disease
Alessandro Tozzi et al.
JOURNAL OF NEUROSCIENCE (2011)
Dopamine induces a GluN2A-dependent form of long-term depression of NMDA synaptic responses in the nucleus accumbens
Karima Chergui
NEUROPHARMACOLOGY (2011)
New advances in NMDA receptor pharmacology
Kevin K. Ogden et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2011)
Onset of pup locomotion coincides with loss of NR2C/D-mediated cortico-striatal EPSCs and dampening of striatal network immature activity
Nathalie Dehorter et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2011)
Synaptic dysfunction in Parkinson's disease
Vincenza Bagetta et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2010)
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
J. C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Carol Kilkenny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Functional heterogeneity of NMDA receptors in rat substantia nigra pars compacta and reticulata neurones
F. Suarez et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2010)
α6β2*and α4β2*Nicotinic Receptors Both Regulate Dopamine Signaling with Increased Nigrostriatal Damage: Relevance to Parkinson's Disease
Xiomara A. Perez et al.
MOLECULAR PHARMACOLOGY (2010)
A subunit-selective potentiator of NR2C-and NR2D-containing NMDA receptors
Praseeda Mullasseril et al.
NATURE COMMUNICATIONS (2010)
N-Methyl-D-aspartate (NMDA) Receptor NR2 Subunit Selectivity of a Series of Novel Piperazine-2,3-dicarboxylate Derivatives: Preferential Blockade of Extrasynaptic NMDA Receptors in the Rat Hippocampal CA3-CA1 Synapse
Blaise Mathias Costa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Extrasynaptic NR2D-Containing NMDARs Are Recruited to the Synapse during LTP of NMDAR-EPSCs
Sarah C. Harney et al.
JOURNAL OF NEUROSCIENCE (2008)
Dopamine D1 receptor inhibition of NMDA receptor currents mediated by tyrosine kinase-dependent receptor trafficking in neonatal rat striatum
Huaxia Tong et al.
JOURNAL OF PHYSIOLOGY-LONDON (2008)
NR2B- and NR2D-containing synaptic NMDA receptors in developing rat substantia nigra pars compacta dopaminergic neurones
S. L. C. Brothwell et al.
JOURNAL OF PHYSIOLOGY-LONDON (2008)
Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism
Xiaoqun Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Cholinergic neurons of the adult rat striatum are immunoreactive for glutamatergic N-methyl-D-aspartate 2D but not N-methyl-D-aspartate 2C receptor subunits
C. Bloomfield et al.
NEUROSCIENCE (2007)
Long-lasting NMDA receptor-mediated EPSCs in mouse striatal medium spiny neurons
Stephen M. Logan et al.
JOURNAL OF NEUROPHYSIOLOGY (2007)
Re-emergence of striatal cholinergic interneurons in movement disorders
Antonio Pisani et al.
TRENDS IN NEUROSCIENCES (2007)
Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons
Zhongfeng Wang et al.
NEURON (2006)
Glutamate-based therapeutic approaches: NR2B receptor antagonists
KR Gogas
CURRENT OPINION IN PHARMACOLOGY (2006)
Functional NR2B- and NR2D-containing NMDA receptor channels in rat substantia nigra dopaminergic neurones
S Jones et al.
JOURNAL OF PHYSIOLOGY-LONDON (2005)
Rationale for and use of NMDA receptor antagonists in Parkinson's disease
PJ Hallett et al.
PHARMACOLOGY & THERAPEUTICS (2004)
Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid
BH Feng et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Frequency-dependent modulation of dopamine release by nicotine
H Zhang et al.
NATURE NEUROSCIENCE (2004)
Nicotine amplifies reward-related dopamine signals in striatum
ME Rice et al.
NATURE NEUROSCIENCE (2004)
The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications
JM Loftis et al.
PHARMACOLOGY & THERAPEUTICS (2003)
Pathophysiology of Parkinson's disease: From clinical neurology to basic neuroscience and back
H Bergman et al.
MOVEMENT DISORDERS (2002)
Functional changes of the basal ganglia circuitry in Parkinson's disease
F Blandini et al.
PROGRESS IN NEUROBIOLOGY (2000)
Share Paper
